{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T19:26:55Z","timestamp":1787772415523,"version":"build-2784847793"},"reference-count":17,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,5]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Many a times while treating dermatoses conventional therapies are either contraindicated or not effective. Intravenous immunoglobulin (IVIG) is a good alternative available to tide over crises.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Method:<\/jats:title>\n                    <jats:p>Over the last 15 years of my practice I have used IVIg in various severe or recalcitrant diseases (including TEN, autoimmune blistering disease, connective tissue disorders, chronic urticaria etc) which were either unresponsive to conventional modality of therapy or primary therapy could not be given because of co-morbidities.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Result:<\/jats:title>\n                    <jats:p>IVIg a sterile, highly purified preparation containing more than 95% unmodified IgG, was first approved by FDA in 1981 for 6 diseases. As mentioned above in many circumstances we reached a situation when either conventional primary therapy was contraindicated or patients were not responding. IVIg came to our rescue in large number of conditions to tide over the crisis and also created the environment leading to conventional therapy becoming effective. Very few minor side effects like low grade fever and myalgia were observed in very few cases. No serious or severe side effects were seen, however, one has to be prepared for anaphylactic reaction which is a theoretical possibility.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>It can be said that IVIg though not a magic drug, is a very effective tool available in the armamentarium of Dermatologists to treat plethora of chronic and intractable dermatoses.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/ijd.ijd_559_17","type":"journal-article","created":{"date-parts":[[2024,5,29]],"date-time":"2024-05-29T12:20:44Z","timestamp":1716985244000},"page":"329","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":2,"title":["Intravenous Immunoglobulin"],"prefix":"10.4103","volume":"66","author":[{"given":"Sanjeev S.","family":"Vaishampayan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Surendra Singh","family":"Bhati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Radha R.","family":"Lachhiramani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shivank","family":"Shrivastava","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prateek","family":"Jain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ajay Singh","family":"Raghuwanshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-21-20240829","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1001\/archderm.134.1.80","article-title":"Dermatological uses of high-dose intravenous immunoglobulin","volume":"134","author":"Jolles","year":"1998","journal-title":"Arch Dermatol"},{"key":"R2-21-20240829","doi-asserted-by":"crossref","first-page":"77","DOI":"10.4103\/0019-5154.48996","article-title":"Intravenous immunoglobulin in dermatology","volume":"54","author":"Dhar","year":"2009","journal-title":"Indian J Dermatol"},{"key":"R3-21-20240829","first-page":"1158","article-title":"Corticosteroid sparing effects of IVIg therapy in patients with pemphigus vulgaris","volume":"138","author":"Hopkins","year":"2002","journal-title":"Arch Dermatol"},{"key":"R4-21-20240829","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1111\/j.1365-2133.2007.08217.x","article-title":"Treatment of pyoderma gangrenosum with intravenous immunoglobulin","volume":"157","author":"Cummins","year":"2007","journal-title":"Br J Dermatol"},{"key":"R5-21-20240829","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1080\/000155500750043131","article-title":"The effectiveness of low-dose intravenous immunoglobulin in chronic urticaria","volume":"80","author":"Kroiss","year":"2000","journal-title":"Acta Derm Venereol"},{"key":"R6-21-20240829","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1046\/j.1365-2133.2003.05486.x","article-title":"Effect of high-dose intravenous immunoglobulin in delayed pressure urticaria","volume":"149","author":"Dawn","year":"2003","journal-title":"Br J Dermatol"},{"key":"R7-21-20240829","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1046\/j.1365-2249.2002.01967.x","article-title":"High-dose intravenous immunoglobulin (hdIVIg) in the treatment of autoimmune blistering disorders","volume":"129","author":"Jolles","year":"2002","journal-title":"Clin Exp Immunol"},{"key":"R8-21-20240829","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1001\/archderm.139.8.1051","article-title":"Consensus statement on the use of intravenous immunoglobulin therapy in the treatment of autoimmune mucocutaneous blistering diseases","volume":"139","author":"Ahmed","year":"2003","journal-title":"Arch Dermatol"},{"key":"R9-21-20240829","doi-asserted-by":"crossref","first-page":"35","DOI":"10.4103\/0378-6323.38405","article-title":"SCORTEN: Does it need modification?","volume":"74","author":"Vaishampayan","year":"2008","journal-title":"Indian J Dermatol Venereol Leprol"},{"key":"R10-21-20240829","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1111\/j.1529-8019.2007.00142.x","article-title":"The use of i.v. IG therapy in dermatology","volume":"20","author":"Fernandez","year":"2007","journal-title":"Dermatol Ther"},{"key":"R11-21-20240829","doi-asserted-by":"crossref","first-page":"5571","DOI":"10.4049\/jimmunol.179.8.5571","article-title":"Intravenous immunoglobulin therapy affects T regulatory cells by increasing their suppressive function","volume":"179","author":"Kessel","year":"2007","journal-title":"J Immunol"},{"key":"R12-21-20240829","first-page":"3523057","article-title":"Intravenous immunoglobulins: Mode of action and indications in autoimmune and inflammatory dermatoses","volume":"2016","author":"Dourmishev","year":"2016","journal-title":"Int J Inflam"},{"key":"R13-21-20240829","first-page":"340","article-title":"Efficacy of combined intravenous immunoglobulins and steroids in children with primary immune thrombocytopenia and persistent bleeding symptoms","volume":"12","author":"Parodi","year":"2014","journal-title":"Blood Transfus"},{"key":"R14-21-20240829","first-page":"143","article-title":"Efficacy of very low-dose (200 mg\/kg\/d) with short-term intravenous immunoglobulin G therapy according to individual response of acute immune thrombocytopenic purpura in childhood","volume":"13","author":"Lee","year":"2006","journal-title":"Clin Pediat Hematol Oncol"},{"key":"R15-21-20240829","doi-asserted-by":"crossref","first-page":"1604","DOI":"10.1345\/aph.1K198","article-title":"Frequency of adverse events associated with intravenous immunoglobulin therapy in patients with pemphigus or pemphigoid","volume":"41","author":"Gurcan","year":"2007","journal-title":"Ann Pharmacother"},{"key":"R16-21-20240829","doi-asserted-by":"crossref","first-page":"153","DOI":"10.2165\/00128071-200405030-00003","article-title":"Efficacy and safety of intravenous immunoglobulin for immune-mediated skin disease: Current view","volume":"5","author":"Ruetter","year":"2004","journal-title":"Am J Clin Dermatol"},{"key":"R17-21-20240829","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1111\/ddg.13013","article-title":"European guidelines (S1) on the use of high-dose intravenous immunoglobulin in dermatology","volume":"15","author":"Enk","year":"2017","journal-title":"J Dtsch Dermatol Ges"}],"container-title":["Indian Journal of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/ijd.IJD_559_17","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T18:45:29Z","timestamp":1787769929000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/ijd.IJD_559_17"}},"subtitle":["Revisited \u2013 My Experience"],"short-title":[],"issued":{"date-parts":[[2021,5]]},"references-count":17,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.4103\/ijd.ijd_559_17","relation":{},"ISSN":["0019-5154"],"issn-type":[{"value":"0019-5154","type":"print"}],"subject":[],"published":{"date-parts":[[2021,5]]}}}